Evidence map›Paper›PMID 41420664›Full record

ReviewInfectious diseases and therapy2026

The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.

Prakhar Srivastava, Elizabeth Singleton, Taylor Morrisette, Andrew David Berti, Remo Lorenzo Ventresca, Emily Brassell, Lyuba Benin, Razieh Kebriaei

Erratum issuedAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Ceftriaxone for methicillin-susceptibleAnnals of medicine · 2026
    Pooled it
  2. Article
  3. Review
  4. Development of a rapid diagnostic test for the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus: Cefinase disk direct (CDD) test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Prakhar SrivastavaP3 Research Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH, USA.
Elizabeth SingletonDepartment of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA.
Taylor MorrisetteDepartment of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA.
Andrew David BertiDepartment of Pharmacy Practice, Wayne State University College of Pharmacy and Health Sciences, Detroit, MI, 48201, USA.
Remo Lorenzo VentrescaP3 Research Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH, USA.
Emily BrassellDepartment of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Lyuba BeninP3 Research Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH, USA.
Razieh KebriaeiP3 Research Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH, USA. Kebriaei.1@osu.edu.ORCID http://orcid.org/0000-0003-4019-2679

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methicillin-susceptible Staphylococcus aureus (MSSA) remains a major cause of morbidity and mortality worldwide, particularly owing to its role in complicated infections including bloodstream infections, osteomyelitis, and infective endocarditis. In 2017, an estimated 119,247 cases of S. aureus bloodstream infections were reported in the USA, resulting in approximately 19,832 deaths. While the prevalence of MSSA varies by region and demographic factors, MSSA has been reported to be approximately two times more common than methicillin-resistant S. aureus (MRSA) in both total and complicated infections. Cefazolin, a first-generation cephalosporin, is widely used for MSSA treatment owing to its favorable safety profile, cost-effectiveness, and availability. However, its efficacy may be compromised by the cefazolin inoculum effect (CzIE)-a phenomenon where cefazolin activity diminishes at high bacterial densities, such as those found in endocardial vegetations or abscesses. Importantly, CzIE is not universally present across all MSSA isolates and geographical areas, with reported prevalence ranging from 0% to 55%. Initially considered a result of producing specific allotypes of the staphylococcal β-lactamase enzyme BlaZ (i.e., allotypes A and C), recent work sheds new light on different BlaZ allotypes associated with the effect while establishing that no single genetic determinant or allotype is uniquely and definitively responsible. When present, CzIE can lead to elevated cefazolin MICs at high inocula, potentially resulting in treatment failure, prolonged hospitalization, and increased mortality. Despite these concerns, clinical data remain inconclusive, and the true impact of CzIE on patient outcomes is still under investigation. This review critically evaluates the molecular basis, clinical relevance, and diagnostic challenges of CzIE, with the goal of informing antibiotic stewardship and optimizing treatment strategies for serious MSSA infections.

Indexed as

Beta-lactamase-MSSACefazolinInoculum effect

Identifiers

PMID41420664
PMCPMC12855670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.